Revance Therapeutic (RVNC) PT Raised to $42 at Needham & Company After Daxi Met All Ph3 Endpoints
Tweet Send to a Friend
Needham & Company analyst Serge Belanger raised the price target on Revance Therapeutic (NASDAQ: RVNC) to $42.00 (from $36.00) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
